Last reviewed · How we verify
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI
Bufomix® Easyhaler® combines an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) to reduce inflammation and bronchodilation in the airways.
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI is a dry powder inhaler developed by Orion Corporation, Orion Pharma. It is a combination of budesonide and formoterol fumarate, used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is not approved by the FDA but is available in other markets. It offers a convenient dosing regimen and is designed to improve patient adherence. The drug has a well-characterized safety profile, with common side effects including upper respiratory tract infections, headache, and pharyngitis.
At a glance
| Generic name | Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI |
|---|---|
| Also known as | Budesonide/formoterol 160/4.5 µg/inhalation dmDPI |
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA) |
| Target | Glucocorticoid receptors and β2-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Budesonide, an ICS, reduces inflammation in the airways by inhibiting multiple types of immune cells and cytokines, while formoterol, a LABA, relaxes smooth muscle in the airways, leading to bronchodilation.
Approved indications
Common side effects
- Upper respiratory tract infection
- Headache
- Pharyngitis
- Nasal congestion
- Cough
- Sore throat
Key clinical trials
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: